FGFR Videos

Vivek Subbiah, MD, Sarah Cannon Research Institute

Videos

Management of Adverse Events Associated With FGFR Inhibitors

12/12/2023

Featuring Vivek Subbiah, MD

Vivek Subbiah, MD, discusses the management of adverse events associated with FGFR inhibitors for urothelial carcinoma and cholangiocarcinoma.

Vivek Subbiah, MD, discusses the...

12/12/2023

Oncology

Antoni Vilaseca, MD, Hospital Clínic de Barcelona

Videos

Novel Erdafitinib Intravesical Delivery System Showed Safety, Efficacy for Patients With Non–Muscle-Invasive Bladder Cancer With Select FGFR Alterations

11/01/2023

Featuring Antoni Vilaseca, MD

Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.

Antoni Vilaseca, MD, discusses...

11/01/2023

Oncology

Vivek Subbiah, MD, MD Anderson Cancer Center

Videos

Next Steps for Pemigatinib on FGFR Inhibition With Multiple Tumors, FDA Approval

04/11/2022

Vivek Subbiah, MD, University of Texas, shares updates of pemigatinib in the upcoming FIGHT-302 study and highlights how an FDA approval will benefit patients with CCA harboring an FGFR2 mutation.

Vivek Subbiah, MD, University of...

04/11/2022

Oncology

Videos

Pemigatinib Safe, Demonstrates Encouraging Responses Among Patients With Advanced Malignancies and an FGFR Mutation: FIGHT-101 Trial

04/01/2022

Vivek Subbiah, MD, University of Texas, overviews the FIGHT-101 trial on pemigatinib, a selective FGFR 1-3 inhibitor, which targets mutations across a variety of tumor types.

Vivek Subbiah, MD, University of...

04/01/2022

Oncology

Videos

Bone Marrow as a Tool to Predict Response to Therapy for MM

02/16/2022

Kareem Azab, PhD, discusses 3D tissue-engineered bone marrow as a tool to predict patient responses to therapy for MM.

Kareem Azab, PhD, discusses 3D...

02/16/2022

Oncology

Videos

Dr Shah Discusses HER-RAM Study Results in HER2+ GI Cancers

06/15/2021

Manish Shah, MD, highlights findings from the phase 1b/2 HER-RAM study. These data were presented at the 2021 ASCO Annual Meeting.

Manish Shah, MD, highlights...

06/15/2021

Oncology

Recent News

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

Conference Coverage

Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.

Results from a phase 2 study...

09/10/2024

Oncology

Conference Coverage

Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.

According to results from the...

09/10/2024

Oncology

Conference Coverage

Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...

According to results from the...

09/10/2024

Oncology

Conference Coverage

Ivonescimab As New First-Line Treatment Option for Patients with PD-L1–Positive, Advanced Non-Small Cell Lung Cancer

09/09/2024

Allison Casey ;

Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.

Ivonescimab showed a clinically...

09/09/2024

Oncology

Conference Coverage

Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer

09/09/2024

Stephanie Holland ;

According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.

According to phase 1/2 study...

09/09/2024

Oncology